COPENHAGEN, July 29 (Reuters) - Novo Nordisk named

Maziar Mike Doustdar as CEO on Tuesday as the Wegovy maker seeks

to revive sales and its share price, hit by worries it is losing

the obesity drug race it started to U.S. rival Eli Lilly ( LLY ).

The appointment comes after the abrupt removal in May of CEO

Lars Fruergaard Jorgensen by Novo and the Novo

Nordisk Foundation - the Danish company's controlling

shareholder.